The National Institute of Allergy and Infectious Diseases (NIAID) offers the Accelerating AIDS Vaccine Development Program (U19) to support the translation of innovative vaccine candidates into early clinical testing. This program aims to assist multi-disciplinary teams in advancing vaccine concepts from down-selection to clinical trials within five years. While funding does not cover clinical studies, applicants are encouraged to collaborate with NIAID-supported networks. Researchers must initiate clinical trials by the end of year five of the award. The closing date for applications is March 13, 2015.
Opportunity ID: 252012
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-14-122 |
| Funding Opportunity Title: | Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.855 — Allergy, Immunology and Transplantation Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 28, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Mar 13, 2015 |
| Current Closing Date for Applications: | Mar 13, 2015 |
| Archive Date: | Apr 13, 2015 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public housing authorities/Indian housing authorities For profit organizations other than small businesses Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses City or township governments Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts County governments Native American tribal governments (Federally recognized) Private institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The goal of the IPCAVD Funding Opportunity Announcement (FOA) is to facilitate the translation of sufficiently advanced, innovative and promising vaccine candidates into early clinical testing. The IPCAVD program is designed to enable a multi-disciplinary team of investigators to complete all steps necessary from down-selection of a vaccine candidate through CGMP manufacture/testing/product release and into clinical trials. A preclinical research application alone is not sufficient for this announcement. Awards will provide the critical resources to allow the advancement of vaccine concepts to clinical trials within the first 5 years of the award. However, this funding opportunity will not provide funds for conducting the clinical studies; applicants are encouraged to collaborate with NIAID-supported clinical trial networks or to develop other relationships to support the clinical studies. Investigators are expected to begin clinical studies no later than year five of the award. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-14-122.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-C | Forms-C | PKG00193435 | Jun 15, 2014 | Mar 13, 2015 | View |
Package 1
Mandatory forms
252012 PHS398_ResearchPlan_2_0-2.0.pdf
252012 PHS398_CoverPageSupplement_2_0-2.0.pdf
252012 RR_KeyPersonExpanded_2_0-2.0.pdf
252012 RR_OtherProjectInfo_1_3-1.3.pdf
252012 PerformanceSite_2_0-2.0.pdf
252012 RR_SF424_2_0-2.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
